Background. In a recent clinical trial, aspirin therapy was initiated ∼34 days after the onset of symptoms but did not reduce the risk of embolism in patients with endocarditis. However, it is possible that aspirin used early in the course of the disease may be beneficial. The purpose of the study is to assess the effect of long-term daily aspirin use on the risk of embolic events in patients with infective endocarditis.
Background. In a recent clinical trial, aspirin therapy was initiated ∼34 days after the onset of symptoms but did not reduce the risk of embolism in patients with endocarditis. However, it is possible that aspirin used early in the course of the disease may be beneficial. The purpose of the study is to assess the effect of long-term daily aspirin use on the risk of embolic events in patients with infective endocarditis.
Methods. The clinical characteristics and outcomes of patients excluded from the Multi-Centre Aspirin Trial in Infective Endocarditis because of long-term aspirin use ( ) were compared with the data for patients n p 84 randomized to the placebo arm ( ). The former patients took aspirin before and during the early stages of n p 55 infective endocarditis, whereas the latter patients were not exposed to aspirin before and during the entire hospitalization. Logistic modeling was used to assess the effect of long-term aspirin use on embolism and bleeding.
Results. There was a trend toward excess bleeding in long-term aspirin recipients, compared with placebo recipients ( ). Logistic modeling revealed that long-term aspirin use may be associated with excess bleeding P p .065 (unadjusted odds ratio, 2.35 [ ]; adjusted odds ratio, 2.08 [ ]), but it had no impact on the risk P p .059 P p .118 of embolic events in either model.
Conclusions. In patients with endocarditis, long-term daily use of aspirin does not reduce the risk of embolic events but may be associated with a higher risk of bleeding. In the acute phase of endocarditis, aspirin should be used with caution.
Embolism remains a dreaded complication in infective endocarditis and tends to occur early in the course of the disease [1] . The incidence of systemic embolism in endocarditis is ∼30% and has not decreased appreciably over the past 30 years, despite improvement in medical treatment [2, 3] . The presence and size of vegetation have been reported to be predictors of increased risk of systemic embolism, but the clinical decision regarding whether to proceed with prophylactic surgery cannot be based on echocardiographic findings alone, because there is no standard method to measure vegetation size, and there is a large overlap in vegetation size between patients with and without embolic events [3, 4] .
Animal studies have found that aspirin may be useful in enhancing the resolution of vegetation and reducing the risk of embolism [5, 6] , but a recent clinical trial failed to demonstrate a beneficial effect of aspirin in this clinical context [2] . It has been suggested that aspirin needs to be used early in the course of disease to have a beneficiary effect in reducing embolic events [7, 8] . The objective of the present study is to assess the effect of long-term daily use of aspirin before the onset of endocarditis on the risks of embolic events in patients prospectively enrolled in the Multi-Centre Aspirin Trial in Infective Endocarditis (MATIE) study.
METHODS
The MATIE study is a multicenter, randomized trial to assess the effect of aspirin on embolic events in the acute phase of infective endocarditis. Endocarditis was diagnosed on the basis of predefined criteria that are similar-but not identical-to the Duke criteria. The design of the study was published elsewhere [2] . Patients were enrolled during the period from July 1994 through June 1998. The exclusion criteria are listed in table 1. Comprehensive clinical and echocardiographic findings at baseline and at the 4-week follow-up visit were prospectively collected from all patients in whom endocarditis was identified during this period. The clinical characteristics and outcomes of patients who were excluded from the study because of long-term daily aspirin use were compared with those for patients randomized to the placebo arm, to assess the effect of long-term aspirin use on the risk of embolic events in infective endocarditis. We also assessed clinical features associated with bleeding and impact of bleeding on outcome in patients with endocarditis.
The main outcome encompassed clinical embolic events involving the brain or other organs in the first 4 weeks after the diagnosis of endocarditis. Clinical evidence of stroke was defined as a new neurologic deficit lasting 124 h. The definition of major bleeding included intracranial or retroperitoneal bleeding, overt bleeding resulting in a decrease of hemoglobin concentration of 120 g/L or requiring blood transfusion, and bleeding into a confined space, causing severe morbidity (e.g., pericardial hematoma and perispinal hematoma). Minor bleeding included all other overt bleeding other than bruising, which did not meet the definition of major bleeding.
The study was approved by the research ethics committees at all of the participating health care centers. Informed consent was obtained from all patients.
Continuous baseline variables are shown as medians with interquartile ranges, and categorical variables are shown as counts and frequencies. The Wilcoxon rank sum test was used to compare baseline differences between the 2 groups of patients for continuous variables, and Fisher's exact test was used for categorical variables.
Logistic regression analysis (univariate and multivariate) was used to evaluate the effect of long-term aspirin use on bleeding and embolism outcomes in this study population. Because this is an observational study, the models of the effect of long-term aspirin use were adjusted for potential confounding factors.
Baseline characteristics in tables 2 and 3 with a P value р.2 were considered for stepwise selection with the models. Patients who experienced bleeding during the hospitalization were compared with those who did not experience bleeding to assess clinical features associated with bleeding. All tests used a P value !.05 for the critical value of statistical significance. Analyses were performed using SAS software, version 9.1.3 (SAS Institute).
RESULTS
During the study period, 560 patients with infective endocarditis were identified and prospectively observed for the entire hospitalization. The overall rate of embolic events was 29%. Of 445 patients excluded from the trial, 84 patients were excluded because of long-term daily aspirin use; the most common dosage was 325 mg per day. Aspirin use was continued during the hospitalization but was stopped if bleeding occurred. The mean duration of aspirin treatment during the hospitalization was days (range, 1-28 days). These patients were compared 26 ‫ע‬ 6 with the 55 patients who received placebo in the randomized trial. The 55 patients had no prior exposure to aspirin and also did not receive aspirin during the hospitalization.
The characteristics of patients in the 2 groups are shown in table 2. Patients with prior cerebrovascular events or heart failure were excluded. Also excluded were patients with a history of bleeding diathesis, gastrointestinal bleeding, or active peptic ulcer disease. Preexisting valvular diseases or conditions, including the presence of a prosthetic valve, were common in both groups. There was a trend toward a greater number of preceding events (other than dental procedures) р12 weeks before hospital admission in the long-term aspirin group, and these events included pneumonia, cellulitis, and recent surgery (e.g., cholecystectomy or endoscopic examinations).
Echocardiography detected vegetation in most patients in both groups, and the location of the valve involvement was similar between the 2 groups (table 3). Blood culture results were frequently positive, and the dominant organisms were Staphylococcus aureus and viridans streptococci in both groups of patients (table 3) .
Clinical outcomes, including in-hospital mortality and systemic embolic events, were similar for the 2 groups (table 4) . There was a trend toward excess bleeding (major or minor) in patients in the long-term aspirin arm ( ), with the ma-P p .065 jority of cases being major bleeding events. There were 13 patients in each group who were receiving concomitant anticoagulant therapy, and bleeding occurred in 3 of these patients in each group. Table 5 summarizes the clinical characteristics and outcomes for patients with and without bleeding during hospitalization. Patients who experienced bleeding had a higher mortality rate and an increased risk of systemic embolism. Independent predictors of bleeding were preceding events in the ). We did not identify any P p .825 other predictors of embolic events or bleeding.
DISCUSSION
Systemic embolic events are common among patients with infective endocarditis and are a major cause of death [3] . Although prophylactic valve surgery has been advocated to prevent embolic events in the subset of patients at high risk, the effectiveness of prophylactic surgery has not been proven [9] . The MATIE study is, to our knowledge, the only randomized trial to assess the effectiveness of aspirin in reducing the risk of embolism in patients with endocarditis who are already receiving antibiotic treatment, and it revealed that a daily dose of aspirin of 325 mg did not reduce the risk of embolism but may increase the risk of bleeding [2] . However the sample size is modest and may be underpowered to detect a small beneficial effect of aspirin on the risk of embolic events. Furthermore, the average duration from the onset of symptoms to initiation of aspirin treatment was ∼34 days [2] . Because embolic events tend to occur early in the course of endocarditis, it is possible that the delay in the initiation of aspirin treatment in the MA-TIE study may have compromised the ability to produce a beneficial effect. The notion of a potential benefit with the early initiation of antiplatelet therapy including aspirin is supported by a recent report by Anavekar et al. [8] ; however, that retrospective study has inherent limitations, including the lack of predefined criteria for embolism and bleeding. In addition, the outcomes were not prospectively collected and validated.
Patients excluded from the randomized MATIE trial because of long-term daily aspirin use represented an ideal group of patients for examination of this issue. All of these patients were treated with long-term aspirin before the development of endocarditis, and all underwent comprehensive prospective follow-up to assess clinical outcomes, including bleeding and embolic events. We purposely rejected comparison with other excluded, nonrandomized patients, because most of those patients had high-risk features associated with worse outcome (table 1) . We chose patients randomized to the placebo arm in the randomized study for comparison, because this group did not have an excess of high-risk features and were not exposed to aspirin treatment before or after the diagnosis of endocar- 
NOTE.
A, intracranial or retroperitoneal bleeding; B, bleeding with a decrease in the hemoglobin concentration of 120 g/L or a requirement of blood transfusion; C, bleeding into a confined space causing severe morbidity, such as pericardial hematoma and perispinal hematoma.
a Some patients had 11 type of major bleeding. ditis. Patients with a history of bleeding diathesis or gastrointestinal bleeding were excluded from both groups. The 2 groups of patients were similar for most clinical characteristics, but patients with prior long-term aspirin use had a tendency toward more bleeding during hospitalization. The association between an increased risk of bleeding and aspirin use was supported by the logistic models, although the association did not quite reach statistical significance. In the adjusted model, in which clinical characteristics, including age, had been taken into consideration, the OR for bleeding was 2.08 ( ) for long-term aspirin recipients. Patients with P p .118 infective endocarditis are at an increased risk of bleeding, likely as a result of the presence of consumptive coagulopathy and of the decrease in production of coagulation factors by the liver [10] . The use of antiplatelet agents, such as aspirin, that perturb the hemostasis pathways can be expected to enhance the risk of bleeding in these patients. The findings of our study support this concern.
In a recent study, Anavekar et al. [8] demonstrated that prior aspirin therapy was associated with a reduced risk of embolic events in patients with infective endocarditis (OR, 0.36; P p ). There was no difference in the risk of embolic events .002 between patients receiving lower dosages of aspirin (р81 mg per day) versus patients receiving higher dosages of aspirin (181 mg per day), with the majority of the latter patients receiving 325 mg per day. Thus, the discordant findings of the present study and the study by Anavekar et al. [8] cannot be entirely explained by the difference in dosages of aspirin. Their study was a large retrospective cohort study that included all adult patients with confirmed diagnosis of infective endocarditis during the period 1980-1998. There were likely significant changes in patient characteristics over such a long span of time. In fact, the diagnostic criteria for endocarditis had changed during this period. Anavekar and colleagues used the propensity score method to adjust for selection bias for receiving antiplatelet therapy, whereas our study analyzed 2 independent populations (placebo recipients vs. long-term aspirin recipients). Compared with patients in the study by Anavekar and colleagues, the patients in the present study likely have a lower risk of complications, because patients with high-risk characteristics, such as prior cerebrovascular event or heart failure, were excluded from the study. The risk of excess bleeding associated with antiplatelet therapy was not presented by Anavekar et al. [8] . Reliable data on the adverse effects associated with antiplatelet therapy would be difficult to detect and quantify in a retrospective study.
Limitations. This is a post-hoc analysis of the database of the MATIE study, although comprehensive clinical and echocardiographic findings were prospectively collected. The 2 groups for comparison were similar in most aspects, but there are differences that we adjusted for in our logistic modeling. Larger prospective trials would be useful to validate the findings of this study and to better define the independent predictors of bleeding and embolism. The ability to enroll a large number of patients with endocarditis is a major challenge, given the relative rarity of the disease. In this study, we examined the effect of aspirin, and it is possible that our findings may not be applicable to other antiplatelet agents, such as clopidogrel. However, in view of the increased risk of bleeding in patients with endocarditis, any agents that affect the hemostasis pathways may further enhance the risk of bleeding in these patients.
Conclusions. In this post-hoc analysis of the MATIE study database, we found that long-term daily use of aspirin did not reduce the risk of embolic events but may be associated with a higher incidence of bleeding in patients with infective endocarditis, similar to the findings of the MATIE randomized trial. Aspirin should be used with caution in the acute treatment of infective endocarditis. For patients who are already taking aspirin and who receive a diagnosis of endocarditis, the need for aspirin should be carefully assessed, and the risk-benefit of discontinuation of aspirin should be considered to minimize the risk of bleeding during the acute phase of endocarditis.
